Dr. Conor Steuer
Claim this profileEmory University Hospital Midtown
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
38 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
KRAS positive
2Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR negative
Affiliated Hospitals
Clinical Trials Conor Steuer is currently running
Defactinib + Avutometinib + Nivolumab
for Lung Cancer
This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Defactinib and avutometinib belong to a class of drugs called kinase inhibitors. These drugs target kinase proteins found in tumor cells. Tumor cells need these proteins to survive and grow. By blocking these proteins, defactinib and avutometinib may cause tumors to stop growing or grow more slowly. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Giving defactinib and avutometinib in combination with nivolumab may kill more tumor cells in patients with anti-PD1 refractory LKB1-mutant advanced non-small cell lung cancer.
Recruiting1 award Phase 29 criteria
MRX-2843 + Osimertinib
for Lung Cancer
This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 120 criteria
More about Conor Steuer
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Conor Steuer has experience with
- Nivolumab
- Pemetrexed
- Durvalumab
- Docetaxel
- Pembrolizumab
- Avutometinib
Breakdown of trials Conor Steuer has run
Lung Cancer
Non-Small Cell Lung Cancer
Thyroid Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Conor Steuer specialize in?
Conor Steuer focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Conor Steuer currently recruiting for clinical trials?
Yes, Conor Steuer is currently recruiting for 7 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Conor Steuer has studied deeply?
Yes, Conor Steuer has studied treatments such as Nivolumab, Pemetrexed, Durvalumab.
What is the best way to schedule an appointment with Conor Steuer?
Apply for one of the trials that Conor Steuer is conducting.
What is the office address of Conor Steuer?
The office of Conor Steuer is located at: Emory University Hospital Midtown, Atlanta, Georgia 30308 United States. This is the address for their practice at the Emory University Hospital Midtown.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.